Salvatore Siena

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 261 publications

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Journal: ESMO gastrointestinal oncology
Published: August 28, 2026

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 01, 2026

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

Journal: Cancer discovery
Published: March 13, 2026

Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort.

Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort.

Journal: Scientific reports
Published: March 12, 2026

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Journal: Nature
Published: February 16, 2026

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.

Journal: ESMO open
Published: February 15, 2026

Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study.

Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Germline genomic profiling of patients with early-onset colorectal cancer.

Germline genomic profiling of patients with early-onset colorectal cancer.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience.

Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience.

Journal: Tumori
Published: February 03, 2026

Locally advanced rectal cancer: what patients and practitioners should know about non-operative management.

Locally advanced rectal cancer: what patients and practitioners should know about non-operative management.

Journal: EClinicalMedicine
Published: December 22, 2025

Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

Journal: Cancer treatment reviews
Published: November 25, 2025

Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomas.

Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomas.

Journal: The oncologist
Published: November 05, 2025
Showing 1-12 of 261

Last Updated: 09/26/2026